Last reviewed · How we verify
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 (100 mg) Vs Placebo When Coadministered With Atorvastatin (10 or 20 mg) in Subjects With Primary Hypercholesterolemia
The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), coadministered with a statin to lower lipid levels in Subjects with Hypercholesterolemia.
Details
| Lead sponsor | Takeda |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 172 |
| Start date | 2004-09 |
| Completion | 2005-02 |
Conditions
- Hypercholesterolemia
Interventions
- Lapaquistat acetate and atorvastatin
- Atorvastatin
Primary outcomes
- Percent change from Baseline in Low Density Lipoprotein Cholesterol — Week 6